S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMAMaria Cristina Pirosa, Davide Rossi, Simone Bocchetta et al.|HemaSphere|2022Cited by 1
CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMAValeria Spina, Davide Rossi, Maria Cristina Pirosa et al.|Hematological Oncology|2021Cited by 0
Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphomaMaria Cristina Pirosa, Davide Rossi, Alessio Bruscaggin et al.|Hematological Oncology|2023Cited by 0